Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency : A randomized controlled trial
GH deficiency is associated with increased cardiovascular mortality and early manifestations of atherosclerosis. Elevated serum homocyst(e)ine levels have been found to be associated with increased cardiovascular risk. The effect of GH replacement on homocyst(e)ine has not been investigated to date....
Gespeichert in:
Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2001-04, Vol.86 (4), p.1518-1524 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1524 |
---|---|
container_issue | 4 |
container_start_page | 1518 |
container_title | The journal of clinical endocrinology and metabolism |
container_volume | 86 |
creator | SESMILO, Gemma BILLER, Beverly M. K LLEVADOT, Joan HAYDEN, Douglas HANSON, Greta RIFAI, Nader KLIBANSKI, Anne |
description | GH deficiency is associated with increased cardiovascular mortality and early manifestations of atherosclerosis. Elevated serum homocyst(e)ine levels have been found to be associated with increased cardiovascular risk. The effect of GH replacement on homocyst(e)ine has not been investigated to date. We evaluated the effect of GH replacement on fasting homocyst(e)inemia in a group of men with adult-onset GH deficiency in a randomized, single blind, placebo-controlled trial. Forty men with adult-onset GH deficiency were randomized to GH or placebo for 18 months, with dose adjustments made according to serum insulin-like growth factor I (IGF-I) levels. Fasting serum homocyst(e)ine, folate, vitamin B12, and total T(3) levels were determined at baseline and 6 and 18 months. Anthropometry, IGF-I levels, insulin, and glucose were measured at 1, 3, 6, 12, and 18 months. Nutritional assessment, body composition, total T(4), thyroid hormone binding index, and free T(4) index were assessed every 6 months. Homocyst(e)ine decreased in the GH-treated group compared with that in the placebo group (net difference, -1.2 +/- 0.6 micromol/L; confidence interval, -2.4, -0.02 micromol/L; P = 0.047). Homocyst(e)ine at baseline was negatively correlated with plasma levels of folate (r = -0.41; P = 0.0087). Total T(3) increased in the GH-treated group vs. that in the placebo group (net difference, 0.17 +/- 0.046 ng/dL; confidence interval, 0.071, 0.26 nmol/L; P = 0.0012). Folate and vitamin B12 levels did not significantly change between groups. Changes in homocyst(e)ine were negatively correlated with changes in IGF-I. For each 1 nmol/L increase in IGF-I, homocyst(e)ine decreased by 0.04 +/- 0.02 micromol/L (P = 0.029). In contrast, changes in homocyst(e)ine did not correlate with changes in folate, vitamin B12, total T(3), C-reactive protein, interleukin-6, or insulin levels. This study shows that GH replacement decreases fasting homocyst(e)ine levels compared with placebo. This may be one of the mechanisms involved in the putative modulation of atherosclerosis and cardiovascular risk by GH replacement. |
doi_str_mv | 10.1210/jc.86.4.1518 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77046813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77046813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-99d588945123d976d334722a025476de65cda80e9cd72eb6d764c6e75ed38c3c3</originalsourceid><addsrcrecordid>eNpF0M9rFDEUB_Agil2rN88SEEoLzpofk2TirZR2Vyh4sdBbSJM3bpZMUpNZy_bkn96ULgqBlwcfvvC-CH2kZEkZJV-3bjnIZb-kgg6v0ILqXnSKavUaLQhhtNOK3R6hd7VuCaF9L_hbdEQp00ootUB_L8cR3FxxHvGvkh_mDd7kMuUE-HS1PsPWTyGFOhc7h5xwe5s8Zbev8ymchaYi_IFYcUh4goQfQgtYrbGHMbgAye3xN3yOi00-T-ERPHY5zSXH2L5zCTa-R29GGyt8OMxjdHN1-fNi3V3_WH2_OL_uHKdi7rT2YhjabZRxr5X0nPeKMUuY6NsGUjhvBwLaecXgTnoleydBCfB8cNzxY3Tykntf8u8d1NlMoTqI0SbIu2qUIr0cKG_wywt0JddaYDT3JUy27A0l5rlxs3VmkKY3z403_umQu7ubwP_Hh4ob-HwAtjobx9aFC_Wf00IKLfkTayqI2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77046813</pqid></control><display><type>article</type><title>Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency : A randomized controlled trial</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>SESMILO, Gemma ; BILLER, Beverly M. K ; LLEVADOT, Joan ; HAYDEN, Douglas ; HANSON, Greta ; RIFAI, Nader ; KLIBANSKI, Anne</creator><creatorcontrib>SESMILO, Gemma ; BILLER, Beverly M. K ; LLEVADOT, Joan ; HAYDEN, Douglas ; HANSON, Greta ; RIFAI, Nader ; KLIBANSKI, Anne</creatorcontrib><description>GH deficiency is associated with increased cardiovascular mortality and early manifestations of atherosclerosis. Elevated serum homocyst(e)ine levels have been found to be associated with increased cardiovascular risk. The effect of GH replacement on homocyst(e)ine has not been investigated to date. We evaluated the effect of GH replacement on fasting homocyst(e)inemia in a group of men with adult-onset GH deficiency in a randomized, single blind, placebo-controlled trial. Forty men with adult-onset GH deficiency were randomized to GH or placebo for 18 months, with dose adjustments made according to serum insulin-like growth factor I (IGF-I) levels. Fasting serum homocyst(e)ine, folate, vitamin B12, and total T(3) levels were determined at baseline and 6 and 18 months. Anthropometry, IGF-I levels, insulin, and glucose were measured at 1, 3, 6, 12, and 18 months. Nutritional assessment, body composition, total T(4), thyroid hormone binding index, and free T(4) index were assessed every 6 months. Homocyst(e)ine decreased in the GH-treated group compared with that in the placebo group (net difference, -1.2 +/- 0.6 micromol/L; confidence interval, -2.4, -0.02 micromol/L; P = 0.047). Homocyst(e)ine at baseline was negatively correlated with plasma levels of folate (r = -0.41; P = 0.0087). Total T(3) increased in the GH-treated group vs. that in the placebo group (net difference, 0.17 +/- 0.046 ng/dL; confidence interval, 0.071, 0.26 nmol/L; P = 0.0012). Folate and vitamin B12 levels did not significantly change between groups. Changes in homocyst(e)ine were negatively correlated with changes in IGF-I. For each 1 nmol/L increase in IGF-I, homocyst(e)ine decreased by 0.04 +/- 0.02 micromol/L (P = 0.029). In contrast, changes in homocyst(e)ine did not correlate with changes in folate, vitamin B12, total T(3), C-reactive protein, interleukin-6, or insulin levels. This study shows that GH replacement decreases fasting homocyst(e)ine levels compared with placebo. This may be one of the mechanisms involved in the putative modulation of atherosclerosis and cardiovascular risk by GH replacement.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.86.4.1518</identifier><identifier>PMID: 11297577</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Biological and medical sciences ; Folic Acid - blood ; Growth Hormone - deficiency ; Growth Hormone - therapeutic use ; Homocysteine - blood ; Homocystine - blood ; Hormones. Endocrine system ; Humans ; Male ; Medical sciences ; Middle Aged ; Nutrition Assessment ; Pharmacology. Drug treatments ; Single-Blind Method ; Thyroid Hormones - blood ; Time Factors ; Vitamin B 12 - blood</subject><ispartof>The journal of clinical endocrinology and metabolism, 2001-04, Vol.86 (4), p.1518-1524</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-99d588945123d976d334722a025476de65cda80e9cd72eb6d764c6e75ed38c3c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=956596$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11297577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SESMILO, Gemma</creatorcontrib><creatorcontrib>BILLER, Beverly M. K</creatorcontrib><creatorcontrib>LLEVADOT, Joan</creatorcontrib><creatorcontrib>HAYDEN, Douglas</creatorcontrib><creatorcontrib>HANSON, Greta</creatorcontrib><creatorcontrib>RIFAI, Nader</creatorcontrib><creatorcontrib>KLIBANSKI, Anne</creatorcontrib><title>Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency : A randomized controlled trial</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>GH deficiency is associated with increased cardiovascular mortality and early manifestations of atherosclerosis. Elevated serum homocyst(e)ine levels have been found to be associated with increased cardiovascular risk. The effect of GH replacement on homocyst(e)ine has not been investigated to date. We evaluated the effect of GH replacement on fasting homocyst(e)inemia in a group of men with adult-onset GH deficiency in a randomized, single blind, placebo-controlled trial. Forty men with adult-onset GH deficiency were randomized to GH or placebo for 18 months, with dose adjustments made according to serum insulin-like growth factor I (IGF-I) levels. Fasting serum homocyst(e)ine, folate, vitamin B12, and total T(3) levels were determined at baseline and 6 and 18 months. Anthropometry, IGF-I levels, insulin, and glucose were measured at 1, 3, 6, 12, and 18 months. Nutritional assessment, body composition, total T(4), thyroid hormone binding index, and free T(4) index were assessed every 6 months. Homocyst(e)ine decreased in the GH-treated group compared with that in the placebo group (net difference, -1.2 +/- 0.6 micromol/L; confidence interval, -2.4, -0.02 micromol/L; P = 0.047). Homocyst(e)ine at baseline was negatively correlated with plasma levels of folate (r = -0.41; P = 0.0087). Total T(3) increased in the GH-treated group vs. that in the placebo group (net difference, 0.17 +/- 0.046 ng/dL; confidence interval, 0.071, 0.26 nmol/L; P = 0.0012). Folate and vitamin B12 levels did not significantly change between groups. Changes in homocyst(e)ine were negatively correlated with changes in IGF-I. For each 1 nmol/L increase in IGF-I, homocyst(e)ine decreased by 0.04 +/- 0.02 micromol/L (P = 0.029). In contrast, changes in homocyst(e)ine did not correlate with changes in folate, vitamin B12, total T(3), C-reactive protein, interleukin-6, or insulin levels. This study shows that GH replacement decreases fasting homocyst(e)ine levels compared with placebo. This may be one of the mechanisms involved in the putative modulation of atherosclerosis and cardiovascular risk by GH replacement.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Folic Acid - blood</subject><subject>Growth Hormone - deficiency</subject><subject>Growth Hormone - therapeutic use</subject><subject>Homocysteine - blood</subject><subject>Homocystine - blood</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nutrition Assessment</subject><subject>Pharmacology. Drug treatments</subject><subject>Single-Blind Method</subject><subject>Thyroid Hormones - blood</subject><subject>Time Factors</subject><subject>Vitamin B 12 - blood</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0M9rFDEUB_Agil2rN88SEEoLzpofk2TirZR2Vyh4sdBbSJM3bpZMUpNZy_bkn96ULgqBlwcfvvC-CH2kZEkZJV-3bjnIZb-kgg6v0ILqXnSKavUaLQhhtNOK3R6hd7VuCaF9L_hbdEQp00ootUB_L8cR3FxxHvGvkh_mDd7kMuUE-HS1PsPWTyGFOhc7h5xwe5s8Zbev8ymchaYi_IFYcUh4goQfQgtYrbGHMbgAye3xN3yOi00-T-ERPHY5zSXH2L5zCTa-R29GGyt8OMxjdHN1-fNi3V3_WH2_OL_uHKdi7rT2YhjabZRxr5X0nPeKMUuY6NsGUjhvBwLaecXgTnoleydBCfB8cNzxY3Tykntf8u8d1NlMoTqI0SbIu2qUIr0cKG_wywt0JddaYDT3JUy27A0l5rlxs3VmkKY3z403_umQu7ubwP_Hh4ob-HwAtjobx9aFC_Wf00IKLfkTayqI2w</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>SESMILO, Gemma</creator><creator>BILLER, Beverly M. K</creator><creator>LLEVADOT, Joan</creator><creator>HAYDEN, Douglas</creator><creator>HANSON, Greta</creator><creator>RIFAI, Nader</creator><creator>KLIBANSKI, Anne</creator><general>Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency : A randomized controlled trial</title><author>SESMILO, Gemma ; BILLER, Beverly M. K ; LLEVADOT, Joan ; HAYDEN, Douglas ; HANSON, Greta ; RIFAI, Nader ; KLIBANSKI, Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-99d588945123d976d334722a025476de65cda80e9cd72eb6d764c6e75ed38c3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Folic Acid - blood</topic><topic>Growth Hormone - deficiency</topic><topic>Growth Hormone - therapeutic use</topic><topic>Homocysteine - blood</topic><topic>Homocystine - blood</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nutrition Assessment</topic><topic>Pharmacology. Drug treatments</topic><topic>Single-Blind Method</topic><topic>Thyroid Hormones - blood</topic><topic>Time Factors</topic><topic>Vitamin B 12 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SESMILO, Gemma</creatorcontrib><creatorcontrib>BILLER, Beverly M. K</creatorcontrib><creatorcontrib>LLEVADOT, Joan</creatorcontrib><creatorcontrib>HAYDEN, Douglas</creatorcontrib><creatorcontrib>HANSON, Greta</creatorcontrib><creatorcontrib>RIFAI, Nader</creatorcontrib><creatorcontrib>KLIBANSKI, Anne</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SESMILO, Gemma</au><au>BILLER, Beverly M. K</au><au>LLEVADOT, Joan</au><au>HAYDEN, Douglas</au><au>HANSON, Greta</au><au>RIFAI, Nader</au><au>KLIBANSKI, Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency : A randomized controlled trial</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>86</volume><issue>4</issue><spage>1518</spage><epage>1524</epage><pages>1518-1524</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>GH deficiency is associated with increased cardiovascular mortality and early manifestations of atherosclerosis. Elevated serum homocyst(e)ine levels have been found to be associated with increased cardiovascular risk. The effect of GH replacement on homocyst(e)ine has not been investigated to date. We evaluated the effect of GH replacement on fasting homocyst(e)inemia in a group of men with adult-onset GH deficiency in a randomized, single blind, placebo-controlled trial. Forty men with adult-onset GH deficiency were randomized to GH or placebo for 18 months, with dose adjustments made according to serum insulin-like growth factor I (IGF-I) levels. Fasting serum homocyst(e)ine, folate, vitamin B12, and total T(3) levels were determined at baseline and 6 and 18 months. Anthropometry, IGF-I levels, insulin, and glucose were measured at 1, 3, 6, 12, and 18 months. Nutritional assessment, body composition, total T(4), thyroid hormone binding index, and free T(4) index were assessed every 6 months. Homocyst(e)ine decreased in the GH-treated group compared with that in the placebo group (net difference, -1.2 +/- 0.6 micromol/L; confidence interval, -2.4, -0.02 micromol/L; P = 0.047). Homocyst(e)ine at baseline was negatively correlated with plasma levels of folate (r = -0.41; P = 0.0087). Total T(3) increased in the GH-treated group vs. that in the placebo group (net difference, 0.17 +/- 0.046 ng/dL; confidence interval, 0.071, 0.26 nmol/L; P = 0.0012). Folate and vitamin B12 levels did not significantly change between groups. Changes in homocyst(e)ine were negatively correlated with changes in IGF-I. For each 1 nmol/L increase in IGF-I, homocyst(e)ine decreased by 0.04 +/- 0.02 micromol/L (P = 0.029). In contrast, changes in homocyst(e)ine did not correlate with changes in folate, vitamin B12, total T(3), C-reactive protein, interleukin-6, or insulin levels. This study shows that GH replacement decreases fasting homocyst(e)ine levels compared with placebo. This may be one of the mechanisms involved in the putative modulation of atherosclerosis and cardiovascular risk by GH replacement.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>11297577</pmid><doi>10.1210/jc.86.4.1518</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-972X |
ispartof | The journal of clinical endocrinology and metabolism, 2001-04, Vol.86 (4), p.1518-1524 |
issn | 0021-972X 1945-7197 |
language | eng |
recordid | cdi_proquest_miscellaneous_77046813 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Adult Biological and medical sciences Folic Acid - blood Growth Hormone - deficiency Growth Hormone - therapeutic use Homocysteine - blood Homocystine - blood Hormones. Endocrine system Humans Male Medical sciences Middle Aged Nutrition Assessment Pharmacology. Drug treatments Single-Blind Method Thyroid Hormones - blood Time Factors Vitamin B 12 - blood |
title | Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency : A randomized controlled trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A27%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20growth%20hormone%20(GH)%20administration%20on%20homocyst(e)ine%20levels%20in%20men%20with%20GH%20deficiency%20:%20A%20randomized%20controlled%20trial&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=SESMILO,%20Gemma&rft.date=2001-04-01&rft.volume=86&rft.issue=4&rft.spage=1518&rft.epage=1524&rft.pages=1518-1524&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.86.4.1518&rft_dat=%3Cproquest_cross%3E77046813%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77046813&rft_id=info:pmid/11297577&rfr_iscdi=true |